1111possibly stroke and heart attack). These new blood vessels are highly damaging as they often fail to deliver a sufficient blood supply, leak fluid and can rupture causing tissue haemorrhage. As a consequence, dysfunctional vessels contribute towards the incidence of a disease (morbidity) and the death rate amongst patients (mortality)...
A Report entitled “Eye Research – an equal partner”, compiled and edited by Julian Jackson, featuring contributions from leading researchers in the UK
This Report aims to drive eye health up the public health agenda, raise awareness of the tremendous legacy and potential of eye research but also highlight the challenges facing eye research including the critical need for greater investment. It points to the vital link between laboratory work and positive clinical...
5.2 Combining treatment and counselling to improve patient outcomes – Julian Jackson
Combining treatment and counselling to improve patient outcomes Julian Jackson Director - Visionbridge New research from Manchester Royal Eye Hospital has concluded that despite the extraordinary scientific achievements in diagnosing and treating serious eye diseases such as wet age related macular degeneration (wAMD), which have revolutionised our ability to reverse...
5.3 The importance of integrating diabetic eye care with diabetes management – Dr Elizabeth Wilkinson
The importance of integrating diabetic eye care with diabetes managementDr Elizabeth WilkinsonConsultant OphthalmologistClinical Lead, North and East Devon Diabetic Screening ProgrammeDr Elizabeth Wilkinson, ex president of the Ophthalmology Section at the Royal Society of Medicine knows that managing diabetes is a complex issue. She is the Clinical Lead for the...
5.1 Patient Power – it actually works! – Professor Philip I. Murray
Patient Power – it actually works! Professor Philip I. MurrayProfessor of Ophthalmologypart of the Birmingham Behçet Centre of Excellence. Behçet’s Syndrome (also known as Behçet’s Disease - BD) is a rare, chronic, multisystem disorder of unknown cause. It is typically characterised by recurrent mouth ulcers, genital ulcers, eye inflammation (uveitis),...
4.2 Technology combined with rehabilitation can improve quality of life for patients – Mr Felipe Dhawahir-Scala
Technology combined with rehabilitation can improve quality of life for patients Mr Felipe Dhawahir-ScalaConsultant Ophthalmologist and Vitreoretinal Surgeon Director of the Acute Ophthalmic Services Manchester Royal Eye Hospital. The CentraSightTM Treatment Programme aims to restore some useful central vision in patients with bilateral end stage age-related macular degeneration who have...
4.3 Enhancing the lifestyles of people who are blind and visually impaired – Shaun Kemp
Enhancing the lifestyles of people who are blind and visually impairedShaun Kemp Marketing Manager UK OrCam TechnologiesOrCam’s mission is to harness the power of artificial vision by incorporating pioneering technology into a wearable platform which improves the lives of individuals who are blind, visually impaired, have a reading disability or...
3.3 Gene therapy options for AMD – Dr. Simon Clark
Gene therapy options for AMDDr. Simon ClarkCentre for Ophthalmology & Vision Sciences Faculty of Medicine and Human Sciences University of ManchesterWhen compared to other therapy options, such as traditional drug based treatments, gene therapy is best suited at the early stages of disease, preferably prior to major physical changes. This...
4.1 Orthoptic research spanning assessment, diagnosis and treatment leading to improved patient care – Professor Helen Davis
Orthoptic research spanning assessment, diagnosis and treatment leading to improved patient careProfessor Helen Davis -Professor of OrthopticsAcademic Unit of Ophthalmology & Orthoptics Department of Oncology & MetabolismThe Medical SchoolThe University of SheffieldDr Anna Horwood Infant Vision Laboratory University of ReadingDr Fiona Rowe VISION research unit University of LiverpoolAt least 10%...
3.1 New corneal therapies: From Bench to Bedside – Professor Keith Meek
New corneal therapies: From Bench to BedsideProfessor Keith MeekProfessor and Chair of Structural Biophysics Research GroupCollege of Biomedical and Life Sciences School of Optometry and Vision SciencesCardiff UniversityAll clinical treatments are underpinned by basic scientific research, sometimes retrospectively, but mostly by forward planning and development, and the UK has historically...